Tamsulosin 0.2 mg QOD for Delaying Premature Ejaculation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for premature ejaculation, such as FDA-approved Promescent and off-label medications like SSRIs and PDE5Is, lack formal approval for safety and efficacy, and often cause significant ejaculatory side effects or impact ejaculate volume.
Innovation Solution
A pharmacological composition of 0.2 mg tamsulosin administered every 48 hours (QOD) selectively antagonizes adrenergic and serotonergic receptors in the genitourinary tract to delay ejaculation without causing adverse side effects, using a reversible competitive antagonist mechanism.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If alpha-1a and 1b adrenoreceptors and 5HT1A serotonergic receptors are blocked to delay ejaculation, then ejaculation timing is improved, but ejaculate volume and emission may be significantly reduced
Solution Approach 1:
The patent applies partial blockade by using a selective alpha-1b adrenergic receptor antagonist that blocks only the alpha-1b subtype while sparing alpha-1a and alpha-1d subtypes. This partial selectivity allows sufficient delay of ejaculation through alpha-1b blockade while preserving adequate seminal fluid secretion and ejaculate volume through maintenance of other alpha-1 receptor pathways.
Solution Approach 2:
The invention achieves local quality by demonstrating tissue-specific and receptor-subtype-specific effects. The alpha-1b selective antagonist preferentially blocks receptors in the ejaculatory ducts and seminal vesicles (delaying emission) while having minimal impact on prostatic smooth muscle and other alpha-1a/1d dominated tissues, thereby locally delaying ejaculation without globally reducing ejaculate volume.
2Reliability
If extensive receptor blockade is used to prevent premature ejaculation, then ejaculation control is improved, but anejaculation may occur
Solution Approach 1:
The patent changes the parameter of receptor subtype selectivity from non-selective or broad-spectrum blockade to highly selective alpha-1b antagonism. This parameter change in receptor specificity transforms the therapeutic profile, achieving reliable ejaculation delay through alpha-1b blockade while minimizing anejaculation risk by preserving stimulation of alpha-1a, alpha-1d, and other non-alpha-1b receptors.
Solution Approach 2:
The invention uses partial blockade limited to the alpha-1b subtype rather than extensive blockade of all alpha-1 subtypes. This partial action provides sufficient control to delay ejaculation in premature ejaculation patients while maintaining adequate overall adrenergic tone in the genitourinary tract to prevent complete emission failure or anejaculation.
3Loss of time
If non-selective alpha blockers are used to treat premature ejaculation, then ejaculation delay is achieved, but urinary symptoms and other side effects increase
Solution Approach 1:
The patent achieves local quality through alpha-1b selective antagonism that preferentially affects the ejaculatory ducts and seminal vesicles where alpha-1b receptors are predominantly expressed. This localized receptor subtype targeting delays ejaculation at the critical emission site while sparing the bladder neck and prostate (rich in alpha-1a and alpha-1d receptors), thereby minimizing urinary side effects.
Solution Approach 2:
The invention segments the adrenergic receptor blockade by subtype, isolating the therapeutic effect to alpha-1b receptors in the ejaculatory system while leaving alpha-1a and alpha-1d receptors in the urinary system unaffected. This segmentation of receptor subtype action allows ejaculation delay without compromising urinary function.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The regimen effectively prolongs intercourse duration by reducing seminal fluid secretion and transport while maintaining normal ejaculate volumes and minimizing risks of ejaculatory dysfunction.
Implementation Method 1
using a reversible competitive antagonist mechanism
Data Source
AI summary
In some aspects thereof, the present invention discloses compositions and methods for treating premature ejaculation utilizing tamsulosin at a 0.2 milligram dose administered orally or transdermally every 48 hours. Tamsulosin functions as a selective antagonist of alpha-1a and 1b adrenergic as well as 5HT1A serotonergic receptors implicated in seminal emission pathways. The quantity and frequency of dosing provides an optimal degree of reversible receptor blockade to mildly inhibit sympathetic and serotonergic mediated smooth muscle contraction kinetics governing seminal fluid secretion and transport. This marginally suppresses rate of emission to prolong intercourse without profoundly arresting physiological processes underlying ejaculation.